DHMEQ-mediated NF-κB inhibition was shown to induce downregulation of NF-κB-dependent anti-apoptotic genes and CLL cell death in vitro [197]. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.